Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MK 8527

Next Previous
Drug Profile

MK 8527

Alternative Names: MK-8527

Latest Information Update: 02 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Merck Sharp & Dohme
  • Class Antiretrovirals; Small molecules
  • Mechanism of Action Nucleoside reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II HIV-1 infections

Most Recent Events

  • 02 Jul 2025 Merck Sharp & Dohme plans a phase III trial for HIV-1 infections (Prevention, In adolescents, In adults, In elderly) (PO, Tablet) in July 2025 (NCT07044297)
  • 17 Jun 2025 Merck Sharp & Dohme plans a phase I pharmacokinetic trial (PO) for in August 2025 (NCT07025551)
  • 04 Jun 2025 Merck Sharp & Dohme completes a phase I trial in HIV-1 infections (In volunteers) (PO) in USA (NCT06826989)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top